• D-Wave’s quantum and quantum-hybrid solutions are uniquely suited for solving today’s optimization problems
• The company’s offerings aim to deliver customer value across several industries including logistics and supply chain, financial services, manufacturing, and life sciences, to name a few
• Boston Consulting Group estimates the near-term TAM for quantum hardware, software and service providers to be $400 million to $1 billion in the next three to five years

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services focused on delivering customer value via practical quantum applications, was recently featured in an article by TBD Media on the Reuters website titled Quantum Computing Emerges as Key to Solving Complex Business Problems (https://ibn.fm/EFJ6j). The company was profiled as one of “50 Leaders of Change” for its work in fueling the adoption of commercial quantum computing solutions, as enterprises seek solutions that help maximize efficiencies, decrease costs, fuel innovation and increase revenue. D-Wave is the world’s first commercial quantum computing company, solving businesses’ most complex computational challenges, spanning areas that include logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fraud detection, and financial modeling.

D-Wave aims to deliver customer value through easy-to-use, practical quantum applications that can address a broad range of businesses’ optimization problems, today. The company delivers quantum hardware, software – including the Leap(TM) quantum cloud service, and services. Its quantum and quantum-hybrid solutions combine the strengths of classical and quantum computing resources to tackle multiple challenges faced by businesses.

“We’re solving real, important problems for businesses. Today’s market environment is forcing business leaders to find new ways to cut costs, improve operational efficiencies and expand revenue. Practical quantum computing is a near-term solution that can help navigate these challenges, now. Enterprises can’t afford to wait,” said Dr. Alan Baratz, CEO of D-Wave. ”As we look to the future, we expect that the types of problems we’ll be able to solve will have unimaginable impact, not only on business but also on society. We expect the D-Wave legacy will be that it was the company that enabled quantum computing for the world and enabled quantum computing to transform all industries to the betterment of society.”

D-Wave’s relentless pursuit of practical quantum computing has resulted in its technology being used by some of the world’s most advanced enterprises, with customers that include more than two dozen Forbes Global 2000 companies. Commercial customers include blue-chip leaders like Volkswagen, Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO and Lockheed Martin.

D-Wave also owns one of the largest quantum computer intellectual property portfolios in the industry, including more than 210 US patents and over 100 peer-reviewed papers in leading scientific journals.

D-Wave’s current commercial product offerings include:

• Advantage(TM) – fifth generation quantum computer
• Leap(TM) – quantum cloud service
• Launch(TM) – quantum computing onboarding service
• Ocean(TM) – full suite of open-source programming tools
• Quantum QuickStart(TM) – quantum computing training

According to Boston Consulting Group, the total addressable market (“TAM”) for quantum hardware, software and service providers is estimated between $400 million and $1 billion over the next three to five years. It is expected to have a substantial impact on multiple industries.

By building both gate-model and annealing quantum computers, D-Wave’s cross-platform approach is expected to bring the power of both models to solve the biggest problems faced by industry (https://ibn.fm/S5b8g). D-Wave is driving near-term impact with long-term potential.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the TAM for quantum computing, the development of D-Wave’s gate model quantum computer and the future impact of D-Wave’s technologies. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

• SideChannel’s Investor Day presentation highlighted the company’s offering as well as gave investors an inside look at what the employees working with the company say about being vCISOs
• SideChannel’s flagship offering is a subscription service that is committed to creating top-tier cybersecurity programs for SMBs to help organizations protect their data and assets
• The company’s holistic approach generates proven results through identification, protection, detection, response, and recovery services, delivered by vCISOs with a combined experience spanning 400-plus years
• The cybersecurity market size is expected to grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027

SideChannel (OTCQB: SDCH), a company simplifying cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time chief information security officer (“CISO”), offers virtual CISOs (“vCISOs”) that possess a combined 400-plus years of experience in cybersecurity covering a wide range of industries. Three SideChannel vCISOs shared their stories during this year’s Investor Day presentation – talking about how working as a vCISO for SideChannel has been a great experience that has allowed them to cater to clients while also making time for their own families (https://ibn.fm/oF91u).

Matt Klein, Patrick Dubois, and Stephen Dye shared what working at SideChannel has meant to them – recounting what it was like working in an office setting before coming to SideChannel and the transition that becoming virtual with SideChannel has made in their lives. The consensus of all three employees revolved around the flexibility of working virtually with clients. Patrick Dubois talked about how in previous settings, grabbing lunch with his wife was impossible – it was something they never got to do. Now, he can grab lunch without clocking out and leaving the office. The full video of Matt, Patrick, and Stephen is available on the company’s YouTube channel (https://ibn.fm/eCY0v).

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created over 50 multi-layered cybersecurity programs for its clients and continues expanding its service offerings, workforce, and customer base. The company has attracted over 20 vCISOs to serve across different industries, including fintech, biotech, healthcare, manufacturing, legal, defense, and technology.

The company’s holistic approach offers proven results through identification, protection, detection, response, and recovery. Reports show that cyberattacks on SMBs have increased in recent years as organizations’ network attack surfaces have grown exponentially, with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications, and third-party suppliers to conduct business.

The cybersecurity market size is expected to grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, expanding at a CAGR of 8.9%. Factors driving this growth include the rise in high-intensity cyberattacks targeting enterprises, the need for compliance and regulatory requirements, and the growing adoption of cloud-based services (https://ibn.fm/tPuOq). SideChannel’s offering includes comprehensive cybersecurity solutions designed to help organizations meet all legal, IT, operational, and risk-related requirements through vCISOs, who monitor and create solutions that work for the individual client’s needs.

SideChannel’s vCISOs and services are designed to give clients exactly what they need, when needed, without any added hassles starting with the initial Risk Assessment. SideChannel uses its experience to facilitate cybersecurity compliance, risk management, uses its Enclave service to simplify micro-segmentation, and more. Working with SideChannel means working with actual CISOs in the private and public sectors with experience solving critical problems for Fortune 500 companies and beyond – transforming how organizations think about cybersecurity.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Government showing strong support for bills aimed at treating Alzheimer’s disease
• IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2
• Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease”

Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued support from the current group of elected officials (https://ibn.fm/8vynv). Support for the treatment of Alzheimer’s is essential for organizations such as India Globalization Capital (NYSE American: IGC), a company pursuing effective treatment for Alzheimer patients suffering with agitation and other neuropsychiatric symptoms.

“The Alzheimer’s Association and the Alzheimer’s Impact Movement (“AIM”) are proud to support the bipartisan introduction of the NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act,” reported a recent Alzheimer’s Association article. “Reintroduced [on Jan. 31, 2023] in Congress, the NAPA Reauthorization Act would extend the National Alzheimer’s Project Act, and the Alzheimer’s Accountability and Investment Act will ensure Congress continues to hear directly from scientists on what resources are needed to prevent and effectively treat Alzheimer’s disease.”

According to the article, the act was first introduced in the 117th Congress, which convened in January 2021. At the time, AIM advocates worked to build bipartisan support for both the NAPA act, eventually landing 65 cosponsors in the House and 27 in the Senate, and the Alzheimer’s Accountability and Investment Act, with 45 cosponsors in the House and 24 in the Senate. AIM representatives noted that they are working to expand that bipartisan progress with the 118th Congress.

“On behalf of the Alzheimer’s community, we thank the Senate and House sponsors for reintroducing these important bipartisan bills to continue the progress we have made in the fight against Alzheimer’s and all other dementia,” said Robert Egge, Alzheimer’s Association chief public policy officer and AIM executive director. “These bills reaffirm our nation’s commitment by helping to secure federal investments in Alzheimer’s research and improve access to better quality care and support services for individuals living with Alzheimer’s and their caregivers. We look forward to working together to pass these bipartisan bills and help improve the lives of those impacted by Alzheimer’s and other dementia throughout the nation.”

AIM isn’t the only organization focused on helping those dealing with Alzheimer’s. IGC’s leading drug candidate, IGC-AD1, recently completed phase 1 of a safety and tolerability trial and entered phase 2 trials. The study, which is the first in humans of a natural low-doses tetrahydrocannabinol (“THC”) compound plus another molecule, is designed to evaluate IGC-AD1 as a treatment for agitation in patients with Alzheimer’s dementia. In addition, IGC has a second drug candidate: TGR-63. An enzyme inhibitor, TGR-63 has shown the potential to reduce neurotoxicity in Alzheimer’s cell lines.

Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

“We believe that IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease as the first and only low-dose natural THC-based formulation candidate currently undergoing FDA trials,” said IGC CEO Ram Mukunda (https://ibn.fm/xU5o9). “Approximately 8 million people are affected by Alzheimer’s in North America and over 55 million worldwide. We believe the diverse population we have selected for this study will allow us to accurately look at both the impact of variations of the gene CYP2C9 that metabolizes THC, as well as APOE e4 a gene that increases the risk of developing Alzheimer’s.

“This data will help us to further understand the metabolism of IGC-AD1 for a diverse population, which is important in treating a disease that has a global impact like Alzheimer’s,” he continued. “Through these and further trials, we look forward to establishing IGC-AD1’s efficacy in treating the symptoms related to Alzheimer’s disease.”

IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain and even pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage. The company operates facilities in the United States under Good Manufacturing Practices.

For more information, visit the company’s website at www.IGCPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

• Rising tension between the US and China requires the country to create new avenues of sourcing and processing REE for use in high-demand industries – increasingly pointing to a North American supply chain for REE facilitated by Ucore
• Ucore’s Unmatched RapidSX(TM) technology combines conventional solvent extraction (“SX”) with a new column-based platform to significantly reduce time-to-completion as well as plant footprint, along with operating costs
• The global REE market is currently around $10 billion – $15 billion per year, with REE being the most efficient form of material for EV motors, enabling $10 trillion to $15 trillion industry-wide for EV vehicles

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a rising company engaged in the separation and scalable production of rare earth elements (“REE”) in the U.S. and Canada, is focused on becoming the leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industries. To date, China has been the dominant leader in providing REE for industries, resulting in dangerous industrial leverage spanning military assets, electric vehicles, wind power generation, as well as mobile phones, and others. However, with the rising tensions between the U.S. and China, Ucore is now positioned to create a North American REE supply chain, allowing the U.S. to become self-sustainable in the industry.

Acquired in 2020 by Ucore, Innovation Metals Corp. developed the RapidSX(TM) separation technology platform with early-stage assistance from the United States Department of Defense, which has resulted in the production of commercial-grade, separated REE at a pilot scale. RapidSX(TM) combines the time-proven chemistry of conventional solvent extraction (“SX”) with a new column-based platform that significantly reduces time to completion and plant footprint, and potentially lowers the capital required and operational costs. SX is the commercial separation technology standard for the international REE industry, and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REE.

The commissioning process is underway for Ucore’s RapidSX(TM) Demonstration Plant in Kingston, Ontario. RapidSX(TM) utilizes similar chemistry to traditional SX technology, but significantly improves the well-established and proven conventional SX separation technology. The demonstration plant is designed to highlight the commercial capabilities of the RapidSX(TM) technology platform, demonstrating the following:

• The techno-economic advantages of the RapidSX(TM) technology platform
• The processing of tens of tons of heavy and light mixed REE concentrates in a simulated production environment over thousands of semi-continuous run-time hours
• Production of high-purity NdPr, praseodymium, neodymium, terbium, and dysprosium REE for early OEM product qualification trials
• The scale-up engineering parameters to full scale production

Ucore’s demo plant is located within the company’s 5,000-square-foot RapidSX(TM) Commercialization and Demonstration Facility and is run by the company’s laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

According to S&P Global, the global REE market is currently around $10 billion – $15 billion per year, with REE being the most efficient form of material for EV motors. Its use has enabled between $10 trillion and $15 trillion of the EV industry. Because of this, REE prices are expected to remain strong over the coming years, since demand is set to increase faster than the supply available (https://ibn.fm/PYxsY).

Ucore is also developing its first full-scale Strategic Metals Complex (“SMC”) REE production plant with the help of KPM and its engineering partner Mech-Chem Associates Inc. in Louisiana with additional potential locations in Alaska and Canada. The Louisiana SMC is scheduled to commence construction in 2023. These SMCs are helping Ucore create a North American REE supply chain that will facilitate the company’s focus on the REE industry in North America without dependency on China.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients
• The company out-licenses the use of its patented DehydraTECH(TM) technology within the pharmaceutical industry and consumer sectors
• Lexaria has focused on applied R&D to establish areas of investigation for commercial pursuits, with its programs proving successful
• Additionally, Lexaria has a robust intellectual property portfolio with 28 patents granted worldwide as of February 2023

In 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology, achieved several important goals for the year, according to CEO Chris Bunka.

“One of our biggest achievements of 2022 was our greater emphasis on commercial pursuits,” Bunka wrote in his January 2023 letter to shareholders (https://ibn.fm/SPqK7). This saw the company acquire new customers, among them Premier Wellness Science Co. Ltd. of Japan, its first client in Asia, BevNology LLC (https://ibn.fm/JWAlF), and AnodGen Bioceuticals (https://ibn.fm/DNZ3q).

This year, the company is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its DehydraTECH technology for both consumer and pharmaceutical sectors. And while Lexaria is not at liberty to go into details, its approach to commercialization has been strategic.

Strategic partnerships involving small to mid-sized biotech as well as large pharmaceutical companies are not new. As reported in a recent article in LabioTech, such partnerships are a better way to build a product’s capabilities and value than outright acquisitions (https://ibn.fm/GeSd1). Additionally, these collaborations provide access to Big Pharma’s infrastructure, resources, and expertise, depending on the terms of the agreements, which can substantially reduce risk.

However, the materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, the article observes, “The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected. This is where patents come in.” Moreover, the clinical development timeframe also matters, with the article noting that “The further a company can take its own research, the better the deal that will be offered in terms of upfront payments, milestone payments, and royalties.”

Lexaria ticks all these boxes. Its unique technology – DehydraTECH  – is not only tangible but has also been shown to enhance the performance of several categories of fat-soluble active molecules and drugs across various oral and topical product formats. The technology is also protected by a robust portfolio of 28 patents granted worldwide as of February 2023. The patents cover method-of-use, composition-of-matter and medical treatment claims for a wide range of active pharmaceutical ingredients (“APIs”), including, but not limited to, cannabidiol (“CBD”), antiviral drugs, vitamins, nicotine, and NSAIDs. Additionally, Lexaria has many more patents pending around the world.

Lastly and perhaps most importantly, Lexaria has substantially invested in research and development (“R&D”), an aspect of its operations that is 100% within its control. According to Bunka, the company has designed its applied R&D to boost its commercial prospects, and this “is paying off in spades,” as it has, among others, “yielded almost entirely positive results.”

In 2022, the company’s top priority was to develop its DehydraTECH-processed CBD hypertension program. The program’s fifth and most comprehensive human clinical study, the HYPER-H21-4, has proven a success. Firstly, the study showed that DehydraTECH-CBD was exceptionally safe, had a high tolerability profile, resulted in a statistically significant decrease of 24-hour ambulatory blood pressure (“BP”), and lowered BP throughout the entire 5-week duration of the study (https://ibn.fm/I2Pz0).

Subsequent results showed that DehydraTECH-CBD achieves better human blood absorption levels at lower doses than non-Lexaria CBD formulations (https://ibn.fm/tXWt9). The study also helped Lexaria discover a novel mechanism of action of the DehydraTECH-CBD capsule formulation in reducing BP (https://ibn.fm/NZvgr). Other applied R&D programs include an oral nicotine program, wherein dosing began late last year, and separate studies evaluating the effect of DehydraTECH-CBD on seizure disorders, diabetes, and dementia.

Lexaria continues to develop appeal to potential collaborators, and its R&D serves as evidence of the resolve to attract investments and partnerships from larger companies.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Corporate Cronyism Hampers Growth and Innovation – Election of Three New Candidates to Board of Directors Proposed

Dissent and disagreement were revealed in a recent preliminary proxy statement from rare disease therapeutics company, Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.). In the preliminary proxy statement released February 27, 2023, the company announced that the Board nominated three directors for re-election at the Company’s Annual Meeting. The proposal to keep the same board after historically poor performance sparked a highly critical response from shareholder Dan Mangless, who has proposed three new candidates and a new direction for the company to unlock the technology and enhance shareholder equity. His letter to Zevra shareholders follows:

Dear Fellow Zevra Therapeutics (formerly KemPharm) Stockholders:

I am a proud owner, like you, of what should be a great pharmaceutical company developing and marketing world class drug products that change lives and creates value for stockholders. With the effective scientific leadership and vision, Zevra’s core technology could be leveraged to develop its existing pipeline and expand it beyond current opportunities to potentially license pipeline products as well as the technology to other pharmaceutical companies eager to enhance their existing portfolios.  With the proper executive and marketing leadership and assuming near-term approval of one or two of the existing pipeline products focused on treating rare diseases, we believe Zevra would quickly become a highly valuable enterprise and potential acquisition target for more established companies looking to enhance their offerings.  An alignment of successful executive and marketing experience with the knowledge and scientific vision associated with Zevra’s core technology would have Zevra on a path to growth and improved stockholder value.

Unfortunately, stockholders have suffered under the leadership of the current Board of Directors.  Rather than recognize their failure to perform, the existing leadership of the Board of Directors has continued to cause the destruction of shareholder value by:

• Failing to instill a culture of accountability.  Zevra has made significant grants of stock options to senior executives while its business was performing poorly, and its stock price was depressed without conditioning at least some of those stock options on company performance.   For example, Zevra awarded its former executive chairman who was retained as CEO 700,000 options priced at the closing share price on January 9, 2023, along with substantial awards to other executives at that time.
• Failing to properly plan for leadership succession. The current leadership of the Board of Directors left Zevra unprepared to pivot to the next generation of executive leadership.  In January 2023, the Board replaced the CEO with its Executive Chairman, who has  a dubious track-record of value creation without exhibiting any attempt to complete a comprehensive search for a new CEO from outside Zevra.
• Failing to align incentives with stockholders.  Board members and executives historically held a very small amount of Zevra shares.  For example, the Executive Chairman held only 9,847 shares prior to his becoming CEO.
• Failing to heed constructive shareholder input and showing little concern for the interests of shareholders.  The Board has not respected the views expressed by stockholders indicated by their voting.  For example, Mr. Joseph Saluri received less than 50% “For” votes from stockholders at the 2021 annual meeting and the Board did not take any action based on such voting.
• Wasting company resources.  Most recently, the Board spent corporate resources on a wasteful “re-branding” exercise in an attempt to distract stockholders from a track record of underperformance.

It is clear from the decisions and actions of Zevra, that a small cohort of potentially conflicted Board members who have been members of the Board for far too long are driving all major decisions of the company while the founder and chief architect of the company’s scientific successes is being completely sidelined to the detriment of the long-term enterprise value of the Company.

Most of the current Board of Directors, including the former Executive Chairman and current CEO and the current Chairman, have been on the Board for more than seven years, including 12 years for the Chairman, which is well beyond the typical service period for directors of publicly traded pharmaceutical companies:

• Matthew Plooster – March 2011 (named Chairman in January 2023)
• Joseph Saluri – January 2014

• Richard Pascoe – January 2014 (named Executive Chairman in November 2021 and CEO in January 2023)
• David Tierney, M.D. – March 2015

Zevra’s Board chose to appoint a chairman who has been with Zevra for the longest period, perpetuating the Board leadership that has held Zevra back from taking a new perspective on its growth.

During their tenure, the company’s share price has fallen precipitously.  In 2015, the stock sold high as $26.15 per share.  The stock was delisted from Nasdaq during 2020 and traded under $0.18 share, ultimately requiring Zevra to execute a 1-for-16 reverse stock split and dilutive fundraising to have its shares listed on Nasdaq again.

POTENTIAL CONFLICT WITH BLUEALLELE

Mr. Saluri’s primary occupation is listed as the Chairman and Chief Executive Officer of BlueAllele, which describes its “mission” as “working to address the unmet therapeutic challenges in gene editing…. based on the core principles of innovating and developing the next level of safe and effective treatments for patients with genetic diseases.”      Until recently, Mr. Pascoe and Mr. Plooster were both listed as “Strategic Advisors” to BlueAllele. The removal of their names and bios from BlueAllele’s public website corresponded with Zevra’s becoming aware of my intent to nominate truly independent nominees at the upcoming annual meeting.

POTENTIAL CONFLICT WITH DEERFIELD

At the time of the 2016 – 2018 proxy filings, Deerfield’s beneficial ownership was almost 10% and, on that basis, Dr. Tierney was elected to the Board.  It does not appear that Deerfield currently owns any shares of the company’s stock.  Despite the liquidation of their holdings and the dilution created through the equity offering to repay the debt obligations to Deerfield in 2021, Dr. Tierney remains on the Board of Directors.

CHIEF EXECUTIVE OFFICER “EXPERIENCE”

Zevra’s January press release announcing the leadership change failed to mention the new CEO’s track record as a chief executive officer, which one would think would be highly relevant in selecting the next CEO of the Company.   Prior to being named Executive Chairman, the new CEO served as the chief executive officer of Histogen Inc.  During the period he served as chief executive officer of Histogen as a publicly listed company, its stock price declined from an opening price of $5.90 on May 26, 2020 to a closing price of $0.73 on November 8, 2021, an 87.6% decline in just 17 months.

PLATFORM TECHNOLOGY PLAN?

Zevra appears to have discarded its LAT platform, which is the foundation of its two FDA approved products, AZSTARYS® and APADAZ®, as well as its lead clinical asset, KP1077.  Zevra has also developed additional LAT-derived products, including KP879, and has referred in its public filings to a large pipeline of preclinical prodrugs in development.  Given this value potential, it would be expected that, in the least, Zevra would be actively seeking to partner or out-license the technology or individual products.  Yet all appearances and recent disclosures suggest the technology, along with its chief inventor, is being cast aside.

Businesses rarely fail from making a single mistake or error.  What causes business to fail over extended periods of time is making the same mistake over and over again, which is the trap Zevra currently finds itself in.  As one of the largest, if not the largest, individual shareholder of Zevra, I have decided enough is enough and it is time to offer a new path with truly independent members of a renewed Board of Directors challenging the status quo and asking the tough questions and holding the Board leadership accountable for the results.  So, this year I have decided to nominate three individuals to join the Board of Directors who have no financial relationship with me but rather will focus on the collective success of all Zevra shareholders.

I anticipate if they are elected my nominees will work with the rest of the Zevra Board of Directors on the following key initiatives:

1. Renew the relationship with the Zevra’s founder with a continued focus on developing the Company’s pipeline from the LAT platform.
2. Conduct a wide and independent search for a chief executive officer with an established track record of success to take Zevra into the future.
3. Push to establish an even more diverse and independent Board of Directors in the future including seeking Board support to eliminate the classified board structure.

My nominees bring a wide-range of experiences in corporate governance, investor relations, finance, health care, R&D strategies, pharmaceutical business development & licensing, insurance reimbursement, patient advocacy as well as mergers and acquisitions and cybersecurity, but most importantly they bring a fresh perspective and independent viewpoint into the board room.

We hope you will read the recently filed preliminary proxy statements and come to the same conclusion we have.

Please join me in supporting the election of John Bode, Douglas Calder and Corey Watton to the Zevra Board of Directors.

I am pleased to engage in further discussion with like-minded stockholders and can be reached via email at renewzevra@gmail.com.

Regards, Dan Mangless

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Third-Party Content The STBN website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the STBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of STBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and STBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by STBN providing you with this internet portal that makes accessible to you the ability to view third party content through the STBN site, STBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. STBN expressly disclaims liability relating to such third-party content. STBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, STBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.stockstobuynow.com/disclaimer/. The disclaimers on the STBN website are applicable to all content provided by STBN, wherever published or re-published are at: https://www.stockstobuynow.com/disclaimer/

• Coyuchi continues to define luxury, sustainability, and circular design, bringing organic cotton into the textile industry for home goods since its inception over 30 years ago
• Its focus has seen the company offer an assortment of products, cutting across bedding, bath, apparel, and lifestyle products and 1,400 SKUs
• With 70% of Coyuchi’s bedding purchases made through department stores, the company is looking to grow its partnerships with even more retailers in 2023

Coyuchi, an organic luxury bed, bath, and apparel company, is committed to expanding its partnerships and aggressively pushing for sustainability practices across all its operations. As a company founded on the idea of creating soft, comfortable, and lasting home textiles using only 100% organic cotton, Coyuchi is defining luxury, sustainability, and circular design, ultimately stamping its position as a leader in this growing environmentally-conscious market.

Since its inception 30 years ago, Coyuchi has sought to bring organic cotton into the textile industry for home goods. This focus has seen the company offer an expanding assortment of bedding, bath, apparel, and lifestyle products, now encompassing approximately 1,400 stock-keeping units (“SKUs”) (https://ibn.fm/A2XaW).

When Coyuchi was founded, according to Eileen Mockus, the company’s President and CEO, “the goal was to bring organic cotton into the textile industry for home goods, and we’ve really taken that mission to heart and are finding ways to expand on it, and continuing to look at the whole process of what we do,” noted Eileen Mockus, the company’s President, and CEO (https://ibn.fm/ZXaSV).

With products sourced sustainably from Germany, India, Portugal, Turkey, and the U.S.A., Coyuchi maintains a tight-knit yet robust supply chain through which it can closely monitor and guarantee the quality and accountability of every raw material that goes into these products. Such a level of commitment and sophistication embodies Coyuchi’s stand on sustainability and accountability while reflecting the luxury tag and value associated with its products.

Currently, 70% of Coyuchi’s bedding purchases are made through department stores, and the company’s management wants to grow its partnerships with other retailers in 2023 to tap into that sector, while also noting that “We’re an online business, and we want to show up with other retailers.”

Coyuchi continues to take advantage of the global cotton market, which is estimated to post a CAGR of 40% by 2028, growing from $518.7 million in 2020 (https://ibn.fm/Q0pfy). Furthermore, with the market currently driven by growing concerns over sustainability and pollution, Coyuchi believes that its unique approach, and strong emphasis on protecting the environment throughout all aspects of its products’ production and final use, will differentiate it from other players in the industry.

Coyuchi is already the gold standard in sustainable luxury home goods. As time progresses, the company will continue to embody the underlying principles that define its brand. With it comes the unlimited growth potential, expanding market share, and strengthening brand equity for a name that has been a staple in the industry for over 30 years.

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• The global waste-to-energy market size is projected to grow from $32.15 billion in 2021 to $44.62 billion in 2029, representing a compound annual growth rate of 4.3 percent
• Sea to Sky Soils (“SSS”), a unit of EverGen Infrastructure Corp., is a leading processor of organic waste in B.C., processes inbound organic waste for a fee, turning it into high-quality organic compost and soils
• In recent weeks, SSS signed multiple contracts for the processing of organic waste at its facility, which provides over 10,000 tonnes per annum. The contract updates provide SSS with increased certainty on the supply of organic feedstock through 2025

Owing to rapid urbanization and bloated landfills, amongst other factors, waste management has become a problem on a global scale. Waste-to-energy is a solution that is gaining traction, turning a liability into an asset while matching government mandates to reduce dependence on fossil fuels and slash emissions across the board. The uptake is beneficial to companies like EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) and its portfolio of projects specialized in converting municipal, agricultural, water, and other types of waste into readily usable energy.

Waste-to-energy is a technologically advanced method of waste management whereby organic material that would otherwise be burned, buried, or left to rot is processed into heat, energy, or other functional products, such as fertilizer. According to Fortune Business Insights, the global waste-to-energy market size is projected to grow from $32.15 billion in 2021 to $44.62 billion in 2029, representing a compound annual growth rate of 4.3 percent.

EverGen, known as “Canada’s Renewable Natural Gas (“RNG”) Infrastructure Platform” because of its market-leading position in the sector, is combating climate change and helping communities contribute to a sustainable future. The British Columbia-based company is partnered with municipalities, corporations, and farms to collect feedstock for its anaerobic digestors that start the process that produces biogas, digestate, or RNG, a green alternative that is indistinguishable from conventional natural gas.

On the downstream side, EverGen has multiple agreements to supply FortisBC, one of Canada’s largest natural gas utilities, with essentially all the RNG it can produce.

The company’s projects and operations include Fraser Valley Biogas, Net Zero Waste Abbotsford, GrowTec, Project Radius, and Sea to Sky Soils. EverGen has four assets generating revenue, two RNG expansions under construction, and one greenfield 3-phase in development. The pipeline includes 8,000,000 gigajoules of RNG production, 1.7 million of which are part of Project Radius in Ontario.

Sea to Sky Soils (“SSS”) is one of the current EverGen revenue generators as an organics processing facility in B.C. SSS is partnered with the Lil’wat Nation, operating on the community’s land since 2012 and employing the majority of staff from the First Nation community while actively supporting it. Working with the indigenous people is in tune with the Sea to Sky Soil’s focus of a circular economy creating top quality soil amendments and blends for use on farms, gardens, and landscapes from local municipal and agricultural waste.

The company processes inbound organic waste for a contracted tipping fee, subsequently converting it into high-quality organic compost and soils for farmers, gardeners, and developers.

In recent weeks, SSS signed multiple contracts with a B.C. regional district for the processing of organic waste at the facility, which provides over 10,000 tonnes per annum. The company has applied to expand permitted capacity to 60,000 tonnes per annum. The contract updates provide SSS with increased certainty on the supply of organic feedstock through 2025 with a preferred partner.

A top processor of organics in B.C., EverGen is committed to own and operate the best-in-class facilities to provide its municipal and commercial partners cost-effective, sustainable solutions for waste. The company is checking all the boxes for sustainability and regional support, including building infrastructure, supplying jobs, providing waste management solutions, helping local agriculture, and generating greenhouse-gas-free energy.

“Contracts such as this de-risk our core business and represent another step towards our goal of providing solutions for over 300,000 tonnes of organic waste per annum in the region,” said Chase Edgelow, CEO of EverGen.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Data443 Risk Mitigation has filed its 2022 Annual Report on Form 10-K with the Securities and Exchange Commission (“SEC”), which marks the fourth full year of audited financial statements filed with the SEC, allowing Data443 to be considered ‘seasoned’ by Nasdaq
• Data443 recently awarded ‘Best for Kiosk’ on their Ransomware Recovery Manager(TM), the only industry solution that actively recovers the device, operating system, and data with a simple reboot
• Data threats are increasingly affecting companies in the U.S., leading to financial and legal repercussions across a swathe of industry players
• The prevalence of remote working has also made a significant difference, with Data443 responding to this opportunity across its portfolio of nine different data security and privacy products
• The company continues to renew and service its existing customer base at a 99% renewal rate (including 20+ fintech companies, thousands of medium-sized businesses, and over 100,000 smaller organizations)

Over the past few years, reports of data breaches have become a near-everyday occurrence. In fact, for one seven-month stretch between December 2019 and June 2020, an array of companies, including Microsoft (December 2019), Estee Lauder (January 2020), Whisper (March 2020), Facebook (April 2020), and Wattpad (June 2020) all announced that they had suffered from data breaches – cumulatively losing over one trillion individual data records in the process. The losses at the time included various data segments, including identification details, purchase histories, and in some cases, payment information. Although breaches can lead to negative publicity and reputational damage for targeted corporations, the repercussions rarely stop there. Following its 2017 breach, which affected nearly 150 million Americans, Equifax faced litigation brought against it by 48 different U.S. states. The firm ended up settling its various enforcement actions for nearly $575 million (https://ibn.fm/U9YQR). Since then, costs have escalated, as have the frequency of attacks. For instance, in 2022, a U.S. company’s average cost of a data breach touched a high of $9.44 million. With 83% of U.S. organizations suffering more than one data breach, protecting their information to prevent future mishaps – and potentially onerous financial liabilities has become a leading corporate priority (https://ibn.fm/nLQZ2).

The increased prevalence of remote working from the COVID-19 pandemic, the industry shift towards cloud-based data storage, and the increasing sophistication of cybercriminals, all led to a surge in data security risks. All those factors were simultaneously at play in June 2020. That month, Sina Weibo, one of China’s largest social media platforms with a model akin to Twitter wherein users communicate via short messages, was hacked. The perpetrators subsequently posted the personal details of over 538 million users – including real names, usernames, gender, location, and in some cases, phone numbers, onto the dark net while offering the entire data set up for sale for a mere $250 (https://ibn.fm/WO2Cl).

Data443 Risk Mitigation (OTC: ATDS), a data security and privacy software company, has centered its mission around preventing the likes of the Sina Weibo hack from ever being repeated, stating its steadfast commitment to identifying and protecting all sensitive data regardless of location, platform or format. The statement has come at a timely juncture, as the ransomware landscape accelerating the rate at which most businesses are adopting data security solutions, and protecting against it has become a global priority. Meanwhile, a recent study by Gartner revealed that by 2024, over 30% of enterprises will have adopted data security platforms, up from less than 5% in 2019.

“The explosion of ransomware, zero-day attacks, third-party breaches, along with long-term remote work concerns & the integration of operational technology with IT systems have culminated into a crisis of confidence for IT security leaders” – IDG Security Priorities Study 2021 (https://ibn.fm/8Q8Hh).

In a similar light, Amazon Simple Storage Service (S3), part of Amazon’s cloud computing operations, recently revealed that they would now encrypt all new objects added on to their cloud servers in response to growing industry concern around misplaced data (https://ibn.fm/3Jyw4). Similarly, Data443 has looked to cater to the needs of an increasing data security-conscious corporate sector through its extensive product suite offering, which boasts a range of solutions designed to securely manage data and data privacy needs on-premises, in the cloud, and in hybrid environments. Some of the key elements included within its product suite include – Data Identification Manager(TM), designed to inventory all data repositories automatically; Data Placement Manager(TM), enabling the secure transfer of sensitive data across public and private networks; Data Archive Manager, a purpose-built tool facilitating information archiving and retention; Data Hound for Collaboration, a data discovery, classification and capture toolset; as well as Ransomware Recovery Manager(TM), an industry-leading solution which can assist users targeted by a hack to recover their device, operating systems and data with a simple reboot.

Gartner recently valued the global cyber security market at $202.72 billion and is projected to expand at a CAGR of 12.3% between 2023 to 2030. Boasting an array of services, including an industry-leading antivirus product and a proprietary anti-ransomware system, Data443 is ideally positioned to benefit from increased online turmoil and rising end demand for its product offering.

Data443 recently filed its annual report on Form 10-K for its fiscal year ending December 31, 2022. Data443 stated in January that it would no longer be subject to the Nasdaq’s higher seasoning threshold for price compliance, an event which the company hopes will hasten its uplisting to the Nasdaq. Data443 was also recently awarded as the ‘Best for Kiosk’ along with the ‘Best for Inexpensive Protection’ from PCMagazine, highlighting its capability to restore your PC to a previous malware-free state, wiping out any changes except your own files.

“We are excited to file our 2022 annual report and no longer be subject to Nasdaq’s 30-of-60-day price requirement for uplisting. We remain hopeful that completing our planned public offering and price compliance at that time will enable the company to complete our uplist to Nasdaq. Doing so will further position the company as a prominent cybersecurity and data management company, and deliver on our business plan, which is our top priority. As stated previously, our efforts to uplist to Nasdaq are central to our continued funding, acquisition strategy, and organic growth efforts,” said CEO and founder Jason Remillard.

Data443 Risk Mitigation, Inc. (ATDS) Investor Relations
Matthew Abenante
ir@data443.com 
919-858-6542

For more information, visit the company’s website at https://data443.com/.

NOTE TO INVESTORS: The latest news and updates relating to ATDS are available in the company’s newsroom at https://ibn.fm/ATDS

• Cybersecurity is a top concern for corporations around the world
• CISO signed an acquisition agreement to expand services into South America
• CEO notes that “cybersecurity requires global capabilities to properly address the security demands of businesses and organizations”

For the second year in a row, cybersecurity and potential cyber incidents are a leading worldwide corporate risk concern. In its continued commitment to provide global services and solutions, Cerberus Cyber Sentinel (NASDAQ: CISO), rebranding to CISO Global, is expanding its existing footprint in Latin America. This move is in keeping with global cyber demand and is seen as a strategic move to address the increasing frequency and cost of cyber incidents worldwide.

Cybersecurity Dive recently noted that “both cyber and business interruptions were the top concerns” for the 2,712 risk management experts surveyed in an Allianz study. The reality is that these incidents translate into hard costs for affected organizations. The most recent IBM Cost of a Data Breach Report shows that last year, the average cost of a data breach hit a record $4.35 million, and the average is expected to surpass $5 million this year. Those incidents add up to a staggering global spend, reaching $1 trillion worldwide, with cyber incidents being considered the “top risk” in 19 countries, including France, Japan, India, the United Kingdom and Canada (https://ibn.fm/Ta4QB).

The article also highlighted who in the marketplace is paying attention to these trends: “The potential threat of ransomware and data breaches has gained the attention of worldwide corporations.” Cybersecurity providers who can help companies unify their approach to network management, cybersecurity, and compliance will be best positioned to address these growing concerns.

With its eyes on continuing to expand its global, unified cybersecurity offering, Cerberus Cyber Sentinel Corp. recently signed a definitive agreement for the acquisition of RAN Security, a cybersecurity company with headquarters in Buenos Aires, Argentina, and offices in Chile, Peru, Bolivia and Paraguay. The company reported that under the terms of the agreement, which is slated to close later this year, RAN Security will become a wholly owned subsidiary of Cerberus Sentinel (https://ibn.fm/9yLWU).

“RAN Security expands our growth strategy in Latin America and adds to our SOC/managed detection and response services,” said Cerberus Sentinel CEO and founder David Jemmett. “Cybersecurity requires global capabilities to properly address the security demands of businesses and organizations. RAN Security is an excellent cultural fit with the Cerberus Sentinel family of companies.”

The announcement noted that RAN Security, which will continue to be based in Argentina, “is part of a growing network of companies acquired by Cerberus Sentinel in Latin America, including Arkavia, CUATROi and NLT, to meet the cybersecurity needs of organizations across the continent.”

Since 2019, the company has grown on three continents: North America, South America and Europe. The company has built a reputation for being an industry leader as a managed cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CerberusSentinel.com.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO